Cargando…
Health economics of disease-modifying therapy for multiple sclerosis in the United States
Multiple sclerosis (MS) is chronic neuroinflammatory condition associated with significant disability. The economic burden of MS is substantial, and high and rising disease-modifying therapy (DMT) prices are the single largest drivers of healthcare expenditures. Over much of the last decade, price i...
Autor principal: | Hartung, Daniel M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894590/ https://www.ncbi.nlm.nih.gov/pubmed/33643441 http://dx.doi.org/10.1177/1756286420987031 |
Ejemplares similares
-
The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs
por: Bebo, Bruce, et al.
Publicado: (2022) -
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
por: Schweitzer, F., et al.
Publicado: (2020) -
Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014) -
Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015) -
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
por: Wiendl, Heinz, et al.
Publicado: (2021)